化学
体内
激酶
酶抑制剂
极光A激酶
极光激酶
体外
生物化学
细胞培养
蛋白激酶A
酶
极光抑制剂
药理学
生物活性
蛋白激酶抑制剂
药物发现
结构-活动关系
口服活性
细胞生物学
酶激活剂
细胞生长
磷酸化
毛茛
作用机理
癌症研究
信号转导
极光激酶B
作者
Yulin Mao,Meiying Zhang,Hao Tang,Jiaguo Li,Jie Wang,Fengtao Zhou,Junhua Zhang,Weixue Huang,Xiaomei Ren,Ke Ding,Zhen Wang
标识
DOI:10.1021/acs.jmedchem.6c00183
摘要
Abstract Discovering novel kinase modulators that combine high selectivity with the ability to regulate noncatalytic functions remains a crucial goal in kinase drug discovery. Here, we use Aurora A as a case study to demonstrate that proteolysis-targeting chimeras (PROTACs) provide a compelling solution to these challenges. We discovered M9101, a potent, selective and in vivo active Aurora A PROTAC degrader, developed from a promiscuous kinase inhibitor warhead. M9101 potently degrades Aurora A with a DC50 value of 2.3 nM in MD-MBA-231 cells and demonstrates exceptional selectivity in a global proteomic analysis. Furthermore, M9101 effectively depletes Aurora A in vivo. This study presents a valuable chemical tool for probing the noncatalytic biology of the kinase and, importantly, highlights that selective kinase degraders are achievable even from promiscuous binding ligands.
科研通智能强力驱动
Strongly Powered by AbleSci AI